

Andrew Freistein 10/786,710

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptabf1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1	Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	"Ask CAS" for self-help around the clock
NEWS 3	SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4	OCT 03 MATHDI removed from STN
NEWS 5	OCT 04 CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS 6	OCT 13 New CAS Information Use Policies Effective October 17, 2005
NEWS 7	OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS 8	OCT 27 Free KWIC format extended in full-text databases
NEWS 9	OCT 27 DIOGENES content streamlined
NEWS 10	OCT 27 EPFULL enhanced with additional content
NEWS 11	NOV 14 CA/CAplus - Expanded coverage of German academic research
NEWS 12	NOV 30 REGISTRY/ZREGISTRY on STN(R) enhanced with experimental spectral property data
NEWS 13	DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 14	DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 15	DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 16	DEC 14 CA/CAplus to be enhanced with updated IPC codes
NEWS 17	DEC 16 MARPATprev will be removed from STN on December 31, 2005
NEWS 18	DEC 21 IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS EXPRESS	DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005. V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT <a href="http://download.cas.org/express/v8.0-Discover/">http://download.cas.org/express/v8.0-Discover/</a>
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

Andrew Freistein 10/786, 710

FILE 'HOME' ENTERED AT 09:57:52 ON 23 DEC 2005

FILE 'REGISTRY' ENTERED AT 09:58:18 ON 23 DEC 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 DEC 2005 HIGHEST RN 870600-23-0  
DICTIONARY FILE UPDATES: 22 DEC 2005 HIGHEST RN 870600-23-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.


\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from  
\* the IDE default display format and the ED field has been added,  
\* effective March 20, 2005. A new display format, IDERL, is now  
\* available and contains the CA role and document type information.  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See **HELP SLIMITS** for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> Uploading C:\Program Files\Stnexp\Queries\10786710\b.str
```




chain nodes :  
19 20 21 22 23 24 25 26 27 28 29 30 31 33  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18  
chain bonds :  
1-20 2-29 10-19 13-27 14-26 15-21 16-22 17-23 18-25 23-24 23-28 29-30.  
30-31 30-33  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 8-11 9-10 9-14 11-12 12-13  
12-15 13-14 13-18 15-16 16-17 17-18  
exact/norm bonds :  
1-20 2-29 5-7 6-10 7-8 8-9 8-11 9-10 9-14 10-19 11-12 12-13 12-15  
13-14 13-18 13-27 14-26 15-16 15-21 16-17 16-22 17-18 18-25 23-24 23-28  
29-30 30-31 30-33  
exact bonds :  
17-23  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6

G1:O,S

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS  
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS  
28:CLASS 29:CLASS 30:CLASS 31:CLASS 33:CLASS

L1 STRUCTURE UPLOADED

=> d  
L1 HAS NO ANSWERS  
L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

```
=> s 11
SAMPLE SEARCH INITIATED 09:58:52 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 42 TO ITERATE

100.0% PROCESSED 42 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 452 TO 1228
PROJECTED ANSWERS: 3 TO 163
```

L2 3 SEA SSS SAM L1

```
=> s 11 full
FULL SEARCH INITIATED 09:58:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 940 TO ITERATE

100.0% PROCESSED 940 ITERATIONS 57 ANSWERS
SEARCH TIME: 00.00.01
```

L3 57 SEA SSS FUL L1

```
=> file hcplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
                           ENTRY SESSION
FULL ESTIMATED COST      161.33 161.54
```

```
FILE 'HCPLUS' ENTERED AT 09:59:00 ON 23 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

Andrew Freistein 10/786,710

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Dec 2005 VOL 144 ISS 1  
FILE LAST UPDATED: 22 Dec 2005 (20051222/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13  
L4 17 L3

=> d ibib hitstr 1-17

L4 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:1036703 HCAPLUS  
 DOCUMENT NUMBER: 141:420412  
 TITLE: Substituted tetracycline compounds for the treatment of malaria  
 INVENTOR(S): Draper, Michael; Nelson, Mark L.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 590 pp., Cont.-in-part of U.S. Ser. No. 128,990, abandoned.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004242548	A1	20041202	US 2003-692563	20031024
US 2004092490	A1	20040513	US 2002-128990	20020424
PRIORITY APPLN. INFO.:			US 2001-286193P	P 20010424
			US 2002-128990	B2 20020424
			US 2002-421259P	P 20021024

OTHER SOURCE(S): MARPAT 141:420412

IT 365277-03-8 365277-04-9 365277-05-0  
 365277-06-1 365277-07-2 365277-23-2  
 365277-24-3 365277-34-5 365277-35-6  
 365277-36-7 365277-38-9 365277-57-2  
 365277-58-3 365277-59-4 365277-60-7  
 365277-61-8 365277-62-9 365277-63-0  
 365277-64-1 365277-65-2 (59809-96-2  
 460070-76-2 460073-80-7 473974-75-3  
 473974-76-4 488817-33-0


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (substituted tetracycline compds. for treatment of malaria)

RN 365277-03-8 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 9H-fluoren-9-ylmethyl ester (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 365277-04-9 HCAPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-05-0 HCAPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 365277-06-1 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-07-2 HCAPLUS

CN Carbamic acid, [(5R,5aS,7S,10aS)-9-(aminocarbonyl)-4-7-bis(dimethylamino)-  
 5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
 naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-23-2 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI)  
 (CA INDEX NAME)

12/27/2005

L4 ANSWER 1 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


Absolute stereochemistry.



RN 365277-24-3 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-methylphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-24-3 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-35-6 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Page 6


L4 ANSWER 1 OF 17 HCAPIPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-bromoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-36-7 HCAPIPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-38-9 HCAPIPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 1 OF 17 HCAPIPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 365277-60-7 HCAPIPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-61-8 HCAPIPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-62-9 HCAPIPLUS  
 CN Carbamothioic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, S-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 17 HCAPIPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 365277-57-2 HCAPIPLUS  
 CN Carbamothioic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, S-phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-58-3 HCAPIPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-bromophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-59-4 HCAPIPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 17 HCAPIPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 365277-63-0 HCAPIPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 3-butene-1-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-64-1 HCAPIPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-65-2 HCAPIPLUS


CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 459809-96-2 HCAPIUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4-(aminomethyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 460070-76-2 HCAPIUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 460073-80-7 HCAPIUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-

Absolute stereochemistry.




RN 473974-75-3 HCAPIUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 473974-76-4 HCAPIUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 488817-33-0 HCAPIUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-

Absolute stereochemistry.




L4 ANSWER 2 OF 17 HCAPIUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004-633439 HCAPIUS  
 DOCUMENT NUMBER: 141-167771  
 TITLE: Tetracycline compounds having target therapeutic activities  
 INVENTOR(S): Levy, Stuart B.; Draper, Michael; Nelson, Mark L.; Jones, Graham  
 PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 277 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004064728	A2	20040805	WO 2004-US1036	20040116
WO 2004064728	A3	20041216		
W: AE, AR, AG, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BR, BW, BY, BY, BZ, CA, CH, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, MZ, NA, NI				
OTHER SOURCE (S): MARPAT 141:167771			US 2003-441141P	P 20030116

IT 365277-03-8 365277-04-9 365277-05-0  
 365277-06-1 365277-22-1 365277-23-2  
 365277-24-3 365277-34-5 365277-35-6  
 365277-36-7 365277-38-9 365277-57-2  
 365277-58-3 365277-59-4 365277-60-7  
 365277-61-5 365277-62-9 365277-63-0  
 365277-64-1 365277-65-2 459809-96-2  
 460070-76-2 460073-80-7 473974-75-3  
 473974-76-4 488817-33-0

RL: PA (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses); (tetracycline compds. with target therapeutic activities)  
 RN 365277-03-8 HCAPIUS  
 CN Carbamic acid, [(5aR,6aS,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-04-9 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 365277-05-0 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-23-2 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-24-3 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-bromoethyl ester (9CI) (CA INDEX NAME)


12/27/2005



RN 365277-06-1 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-22-1 HCAPLUS

CN Cholest-5-en-3-ol (3B)-, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]carbamate (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



RN 365277-34-5 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-35-6 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-bromoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-36-7 HCAPLUS


L4 ANSWER 2 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-38-9 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-57-2 HCPLUS  
 CN Carbamothioic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, S-phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 2 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 365277-61-8 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-62-9 HCPLUS  
 CN Carbamothioic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, S-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-63-0 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 3-butetyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 365277-58-3 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-bromophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-59-4 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-60-7 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 2 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 365277-64-1 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-65-2 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 459809-96-2 HCPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4-(aminomethyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 460070-76-2 HCAPLUS

CN Carbamic acid,

(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 460073-80-7 HCAPLUS

CN Carbamic acid,

(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473974-75-3 HCAPLUS

CN Carbamic acid,

(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

ACCESSION NUMBER: 2004:371069 HCAPLUS

DOCUMENT NUMBER: 140:386006

TITLE: Substituted tetracycline compounds for the treatment of malaria

INVENTOR(S): Draper, Michael; Nelson, Mark L.

PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 161 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004038001	A2	20040506	WO 2003-US33927	20031024
WO 2004038001	A3	20041111		
W: AB, AG, AL, AM, AT, AU, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MN, MM, MZ, NI, NO, NZ, OH, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TH, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, PT, RU, TZ, TH, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502464	AA	20040506	CA 2003-2502464	20031024
EP 1556007	A2	20050727	EP 2003-781393	20031024
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.: US 2002-421259P			P 20021024	
		WO 2003-US33927	W 20031024	

OTHER SOURCE(S): MARPAT 140:386006

IT 365277-03-9 365277-04-9 365277-05-0

365277-06-1 365277-07-2 365277-23-2

365277-24-3 365277-34-5 365277-35-6

365277-38-0 365277-39-1 365277-50-2

365277-53-9 365277-59-4 365277-60-7

365277-62-9 365277-63-0 365277-63-0

365277-64-1 365277-65-2 459809-96-2

460070-76-2 460073-80-7 473974-75-3

473974-76-4 488817-33-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Substituted tetracycline derivs. for malaria treatment)


RN 365277-03-8 HCAPLUS

CN Carbamic acid, [(5aR,6aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-

(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



RN 473974-76-4 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 488817-33-0 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-04-9 HCAPLUS

CN Carbamic acid, [(5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-05-0 HCAPLUS

CN Carbamic acid, [(5aR,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-06-1 HCAPLUS


L4 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-07-2 HCAPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-23-2 HCAPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 365277-24-3 HCAPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-methylphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-34-5 HCAPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-35-6 HCAPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-


L4 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 (dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-bromoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-36-7 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-38-9 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-57-2 HCAPLUS  
 CN Carbamothioic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-


L4 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, S-phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-50-3 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-bromophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-59-4 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-60-7 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-

L4 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-61-8 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-62-9 HCAPLUS

CN Carbamothioic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl-, S-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-63-0 HCAPLUS

L4 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl-, 3-but enyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-64-1 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl-, phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-65-2 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl-, 2-methylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 459809-96-2 HCAPLUS  
 Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4-(aminomethyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460070-76-2 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-80-7 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl-, 2-propynyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 3 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 473974-75-3 HCAPLUS  
 Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 473974-76-4 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488817-33-0 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:371068 HCAPLUS  
 DOCUMENT NUMBER: 140:386057  
 TITLE: Methods of using substituted tetracycline compounds  
 to modulate RNA, and therapeutic use  
 INVENTOR(S): Levy, Stuart B.; Draper, Michael; Jones, Graham;  
 Nelson, Mark L.  
 PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 124 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004038000	A2	20040506	WO 2003-US33926	20031024
WO 2004038000	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GO, GW, MU, MR, NE, SN, TD, TG				
CA 2503446	RA	20040506	CA 2003-2503446	20031024
US 2004214800	A1	20041028	US 2003-692764	20031024
EP 1562608	A2	20050817	EP 2003-781397	20031024
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2002-421248P	P 20021024
				WO 2003-US33926 W 20031024

OTHER SOURCE(S): MARPAT 140:386057  
 IT 365277-03-8 365277-04-9 365277-05-0  
 365277-06-1 365277-22-1 365277-23-2  
 365277-24-3 365277-34-1 365277-35-6  
 365277-36-7 365277-38-9 365277-57-2  
 365277-58-3 365277-59-4 365277-60-7  
 365277-61-8 365277-62-2 365277-63-0  
 365277-64-1 365277-65-2 460070-76-2  
 460073-80-7 473974-75-3 473974-76-4  
 498817-33-0  
 RL: PRC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (RNA-modulating substituted tetracycline compds., and therapeutic use)  
 RN 365277-03-8 HCAPLUS  
 CN Carbanic acid, ((5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-


L4 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 5-methyl-10,12-dioxo-2-naphthacenyl)-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-04-9 HCAPLUS  
 CN Carbanic acid, ((5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl)-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-05-0 HCAPLUS  
 CN Carbanic acid, ((5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl)-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 365277-06-1 HCAPLUS  
 CN Carbanic acid, ((5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-22-1 HCAPLUS  
 CN Cholest-5-en-3-ol (3B)-, ((5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl) carbamate (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



12/27/2005


L4 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B




RN 365277-23-2 HCAPLUS  
 CN Carbanic acid, ((5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl)-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-24-3 HCAPLUS  
 CN Carbanic acid, ((5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl)-, 4-methylphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-34-5 HCAPLUS

Page 14


L4 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Carbamic acid, [(5R, 5aR, 6S, 6aR, 7S, 10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-35-6 HCAPLUS  
 CN Carbamic acid, [(5R, 5aR, 6S, 6aR, 7S, 10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-bromoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-36-7 HCAPLUS  
 CN Carbamic acid, [(5aR, 6aS, 7S, 10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 365277-38-9 HCAPLUS  
 CN Carbamic acid, [(5aR, 6aS, 7S, 10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-57-2 HCAPLUS  
 CN Carbamothioic acid, [(5aR, 6aS, 7S, 10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, S-phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-58-3 HCAPLUS  
 CN Carbamic acid, [(5aR, 6aS, 7S, 10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-bromophenyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 365277-59-4 HCAPLUS  
 CN Carbamic acid, [(5aR, 6aS, 7S, 10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-60-7 HCAPLUS  
 CN Carbamic acid, [(5aR, 6aS, 7S, 10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-61-8 HCAPLUS  
 CN Carbamic acid, [(5aR, 6aS, 7S, 10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, butyl ester (9CI) (CA INDEX NAME)

12/27/2005


L4 ANSWER 4 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 365277-62-9 HCAPLUS  
 CN Carbamothioic acid, [(5aR, 6aS, 7S, 10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, S-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-63-0 HCAPLUS  
 CN Carbamic acid, [(5aR, 6aS, 7S, 10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 3-but enyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-64-1 HCAPLUS  
 CN Carbamic acid, [(5aR, 6aS, 7S, 10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-65-2 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

## Absolute stereochemistry.




RN 460070-76-2 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

## Absolute stereochemistry.




RN 460073-80-7 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propynyl ester (9CI) (CA INDEX NAME)

## Absolute stereochemistry.




## Absolute stereochemistry.




RN 473974-75-3 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

## Absolute stereochemistry.



RN 473974-76-4 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)

## Absolute stereochemistry.



RN 488817-33-0 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-

TITLE: Preparation of substituted tetracycline compounds for the treatment of bacterial infections and neoplasms  
 INVENTOR(S): Nelson, Mark L.; Obemeng, Kwasi; Frechette, Roger; Abato, Paul; Assefa, Hagegewein; Bandara, Upali; Bernaci, Joel; Bhatia, Bina; Chen, Jackson; Ismail, Mohamed; Kim, Oak A.; Mathew, Jude; McIntyre, Laura; Ndalawali, Mohamed; Pearson, Andrei; Reddy, Lakshmi; Sheahan, Paul; Sizensky, Emmanuel; Tourigny, Justin; Verma, Atul K.; Viski, Peter; Warchol,

Tadeusz.

PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 118 pp.DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003079984	A2	20031002	WO 2003-US8324	20030318
WO 2003079984	A3	20040910		
W: AZ, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DN, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SL, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BT, BJ, CF, CG, CI, GN, IQ, IQ, KW, MR, NE, SN, TG, CA 247984 AA 20031002 EP 2003-247987 20030318 EP 1503901 A2 20050209 EP 2003-714236 20030318				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MK, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	T2	20050714	JP 2003-577816	20030318
JP 200520846			US 2003-740961	20031218
US 2005038002	A1	20050217	US 2003-366915P	P 20020321
PRIORITY APPLN. INFO.:				
			US 2002-367045P	P 20020321
			US 2002-367048P	P 20020321
			US 2002-395468P	P 20020712
			US 2003-440305P	P 20030114
			US 2003-391903	B1 20030318
			WO 2003-US8324	W 20030318


OTHER SOURCE(S): MARPAT 139:292094

IT 460073-80-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L4 ANSWER 5 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
(prepn. of tetracycline compds. for the treatment of bacterial infections and neoplasms)  
RN 460073-80-7 HCAPLUS  
CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthalenyl]-, 2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 6 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
ACCESSION NUMBER: 2003:678826 HCAPLUS  
DOCUMENT NUMBER: 139:224449  
TITLE: Insulin and IGF-1 receptor peptide agonists and antagonists, and therapeutic use  
INVENTOR(S): Pillutla, Renuka; Brissette, Renée; Blume, Arthur J.; Schaffer, Lauges; Brandt, Jakob; Goldstein, Neil I.; Spetzler, Jane; Ostergaard, Soren  
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; DGI Biotechnologies  
SOURCE: PCT Int. Appl., 328 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 5  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070747	A2	20030828	WO 2002-US30312	20020924
WO 2003070747	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
US 2003195147	A1	20031016	US 2001-962756	20010924
US 6875741	B2	20050405		
CA 2460055	AA	20030828	CA 2002-2460055	20020924
EP 1496935	A2	20050119	EP 2002-806867	20020924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005517741	T2	20050616	JP 2003-569654	20020924
PRIORITY APPLN. INFO.: US 2001-962756 A2 20010924				
US 1998-146127 B2 19980902				
US 2000-538038 A2 20000329				
WO 2002-US30312 W 20020924				

OTHER SOURCE(S): MARPAT 139:224449  
IT 365277-84-5P  
RL: BPN (Biosynthetic preparation); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(peptides from various peptide libraries, their dimers and fusion proteins as modulators of insulin and IGF-1 receptors)  
RN 365277-84-5 HCAPLUS  
CN Carbamothioic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-

L4 ANSWER 6 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
10,12-dioxo-2-naphthalenyl]-, O-(4-fluorophenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 7 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
ACCESSION NUMBER: 2003:57866 HCAPLUS  
DOCUMENT NUMBER: 138:117673  
TITLE: Tetracycline compounds having target therapeutic activities  
INVENTOR(S): Levy, Stuart B.; Draper, Michael; Nelson, Mark L.; Jones, Graham  
PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA  
SOURCE: PCT Int. Appl., 158 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003005971	A2	20030123	WO 2002-US22451	20020715
WO 2003005971	A3	20031127		
WO 2003005971	C1	20040506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
US 2004063674	A1	20040401	US 2002-196010	20020715
EP 1408987	A2	20040421	EP 2002-748169	20020715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2004537544	T2	20041216	JP 2003-511780	20020715
PRIORITY APPLN. INFO.: US 2001-305546P P 20010713				
US 2002-395741P P 20020712				
WO 2002-US22451 W 20020715				

OTHER SOURCE(S): MARPAT 138:117673  
IT 365277-03-8 365277-04-9 365277-05-0  
365277-06-1 365277-22-1 365277-23-2  
365277-24-3 365277-34-9 365277-35-6  
365277-36-7 365277-38-9 365277-57-2  
365277-58-3 365277-59-4 365277-60-7  
365277-61-8 365277-62-9 365277-63-0  
365277-64-1 365277-65-2 459809-96-2  
460070-76-2 460073-80-7 473974-75-3  
473974-76-4 488817-33-0  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(tetracycline compds. with target therapeutic activities)  
RN 365277-03-8 HCAPLUS  
CN Carbamic acid, [(5R,5aR,6aS,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthalenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-04-9 HCAPIUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 365277-05-0 HCAPIUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-23-2 HCAPIUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-24-3 HCAPIUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-bromoethyl ester (9CI) (CA INDEX NAME)


12/27/2005



RN 365277-06-1 HCAPIUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-22-1 HCAPIUS

CN Cholest-5-en-3-ol (3 $\beta$ )-, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]carbamate (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



RN 365277-34-5 HCAPIUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-35-6 HCAPIUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-bromoethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-36-7 HCAPIUS


L4 ANSWER 7 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-38-9 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-57-2 HCPLUS  
 CN Carbamothioic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, S-phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 7 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 365277-61-8 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-62-9 HCPLUS  
 CN Carbamothioic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, S-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-63-0 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 3-butenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 7 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 365277-58-3 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-bromophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-59-4 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-60-7 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 7 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 365277-64-1 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-65-2 HCPLUS  
 CN Carbamic acid,  
 [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 459809-96-2 HCPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4-(aminomethyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 460070-76-2 HCAPLUS

CN Carbamic acid,

(5aR,6aS,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 460073-80-7 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl-, 2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473974-75-3 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

TITLE: Substituted tetracycline compounds for the treatment of malaria

INVENTOR(S): Drapet, Michael; Nelson, Mark L.; Frechette, Roger

PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 89 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085303	A2	200201031	WO 2002-US12935	20020424
WO 2002085303	A3	200305155		
W:	AF, AG, AL, AR, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, BE, ES, FI, GB, GD, GE, GH, GI, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
TM:	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BE, BJ, CF, CG, CL, CH, GN, GO, GR, HL, HR, NE, SN, TD, TG			
CA 2444899	AA	20021031	CA 2002-2444899	20020424
EP 1399414	A2	20040324	EP 2002-723955	20020424
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE, MC, PT, IB, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004052992	T2	20040930	JP 2002-582879	20020424
PRIORITY APPLN. INFO.:			US 2001-286193P	P 20010424
			WO 2002-US12935	W 20020424

OTHER SOURCE(S): MARPAT 137:333118

IT 365277-22-1 365277-23-2 365277-38-9

365277-57-2 365277-59-4 365277-60-7

365277-63-0 473974-75-3 473974-76-4


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

RN 365277-22-1 HCAPLUS

CN Cholesta-5-en-3-ol (3B)-, [(5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]carbamate (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



RN 473974-76-4 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 488817-33-0 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A




PAGE 1-B



RN 365277-23-2 HCAPLUS

CN Carbamic acid, [(5aR,6aS,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-38-9 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-


L4 ANSWER 8 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-57-2 HCPLUS  
 CN Carbamothioic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, S-phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-59-4 HCPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 8 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 473974-76-4 HCPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 8 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-63-0 HCPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 3-butetyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473974-75-3 HCPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 9 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2002-716234 HCPLUS  
 DOCUMENT NUMBER: 137:247552

TITLE: Preparation of 7, 9-substituted tetracycline derivatives for pharmaceutical use as antibacterial agents

INVENTOR(S): Nelson, Mark L.; Frechette, Roger; Viski, Peter; Ismail, Mohamed; Bowser, Todd; McIntyre, Laura; Bhatia, Beena; Hawkins, Paul; Reddy, Laxma;

Stapleton,

PATENT ASSIGNEE(S): Karen: Warchol, Ted; Sheahan, Paul  
 Paratek Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 54 pp.

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072532	A1	20020919	WO 2001-US20722	20010629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NC, NL, NZ, PL, PT, RO, RU, SE, SG, SI, SL, TJ, TN, TR, TZ, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TO, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TM, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, IE, IT, LU, MG, NL, PT, SE, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2440383	A1	20020919	CA 2001-2440383	20010629
US 2002193354	A1	20021219	US 2001-895797	20010629
US 6633063	B2	20040127		
EP 1368305	A1	20031210	EP 2001-950651	20010629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005056291	T2	20050303	JP 2002-571448	20010629
BR 2001016935	A	20050412	BR 2001-16935	20010629
ZA 2003007239	A	20041117	ZA 2003-7239	20030916
US 2004138163	A1	20040715	US 2003-738862	20031216
PRIORITY APPLN. INFO.:			US 2001-275620P	P 20010313
			US 2001-895797	A1 20010629
			WO 2001-US20722	W 20010629

OTHER SOURCE(S): MARPAT 137:247552  
 IT 459809-96-2P

AL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses);  
 (Preparation of 7, 9-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

RN 459809-96-2 HCPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4-(aminomethyl)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072031	A2	20020919	WO 2002-US7829	20020314
WO 2002072031	A3	20031113		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TU, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, A2, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, PT, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HM, MR, NG, SN, TD, TZ				
CA 2440757	AA	20020919	CA 2002-2440757	20020314
US 2003166585	A1	20030904	US 2002-97634	20020314
EP 1381372	A2	20040121	EP 2002-750617	20020314
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005504723	T2	20050217	JP 2002-570991	20020314
US 2005070510	A1	20050331	US 2004-943571	20040916
PRIORITY APPLN. INFO.:			US 2001-275899P	P 20010314
			US 2002-97634	A1 20020314
			WO 2002-US7829	W 20020314

OTHER SOURCE(S): MARPAT 137-244598

IT 365277-03-8 365277-07-2 365277-23-2

365277-35-6 365277-36-7 365277-38-9

365277-60-7 365277-61-8 365277-62-9

365277-63-0 365277-65-2 459809-86-2

460070-76-2 460073-80-7

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)


RN 365277-03-8 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-

(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-bromoethyl ester (9CI) (CA INDEX NAME)

(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 9H-fluoren-9-ylmethyl ester (9CI)


Absolute stereochemistry.



RN 365277-07-2 HCAPLUS

CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-23-2 HCAPLUS


CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-bromoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-36-7 HCAPLUS

CN Carbamic acid,

[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-38-9 HCAPLUS


CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 10 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 RN 365277-60-7 HCAPLUS  
 CN Carboxamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-61-8 HCAPLUS  
 CN Carboxamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-62-9 HCAPLUS  
 CN Carbamothioic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, S-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 10 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 460070-76-2 HCAPLUS  
 CN Carboxamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 460073-80-7 HCAPLUS  
 CN Carboxamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 10 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 365277-63-0 HCAPLUS  
 CN Carboxamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 3-butene-1,2-dioxo-2-naphthacenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-65-2 HCAPLUS  
 CN Carboxamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 459809-96-2 HCAPLUS  
 CN Carboxamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4-(aminomethyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002-716027 HCAPLUS

DOCUMENT NUMBER: 137:244597

TITLE: Substituted tetracycline compounds as antifungal agents

INVENTOR(S): Draper, Michael; Nelson, Mark L.

PATENT ASSIGNEE(S): Paratek Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072022	A2	20020919	WO 2002-US7502	20020314
WO 2002072022	A3	20031016		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DM, DZ, EC, ES, FI, GB, GD, GE, GH, GI, HR, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RU, SD, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, VN, YU, ZA, ZM, ZW, ZR, ZT, UG, ZM, ZW, AM, AZ, BY, KG, KZ, KU, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, ME, PI, SE, TR, BF, BJ, CR, CG, CI, CH, GA, GN, GO, GM, MR, NE, SN, TD, TG				
CA 2457234	AA	20020919	CA 2002-2457234	20020314
US 2003100017	A1	20030529	US 2002-97457	20020314
US 6841546	B2	20050111		
EP 1379255	A2	20040114	EP 2002-721365	20020314
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, SI, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004530661	I2	20041007	JP 2002-570982	20020314
US 2005020545	A1	20050127	US 2004-921580	20040618
PRIORITY APPLN. INFO.:			US 2001-275948P	P 20010314
			US 2002-97457	A3 20020314
			WO 2002-US7502	W 20020314

OTHER SOURCE(S): MARPAT 137:244597

IT 365277-36-7


RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)

RN 365277-36-7 HCAPLUS  
 CN Carboxamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 11 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STI

(Continued)



14 ANSWER 12 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2002:51419 HCPLUS  
 DOCUMENT NUMBER: 136:102231  
 TITLE: Preparation of 9-substituted minocycline derivatives  
 for pharmaceutical use as antibacterial agents  
 INVENTOR(S): Nelson, Mark L.; Frechette, Roger; Viski, Peter;  
 Ismail, Mohamed; Bowers, Todd; Dumontier, Jimmy;  
 Rennie, Glen; Liu, Gui; Koza, Darrell; Sheahan, Paul;  
 Stapleton, Karen; Hawkins, Paul; Bhatia, Beena;  
 Verma,  
 PATENT ASSIGNEE(S): Atul; McIntyre, Laura; Warchol, Tad  
 Trustees of Tufts College, USA; Paratek  
 Pharmaceuticals, Inc.  
 SOURCE: PCT Int. Appl., 57 pp.  
 CODEN: PIXKD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200204406	A2	20020117	WO 2001-US20721	20010629
WO 200204406	A3	20020606		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HK, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2415178	AA	20020117	CA 2001-2415178	20010629
EP 1301467	A2	20030416	EP 2001-965828	20010629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012269	A	20030701	BR 2001-12269	20010629
US 2003125348	A1	20030703	US 2001-895857	20010629
US 6846939	B2	20050125		
JP 2004502752	T2	20040129	JP 2002-509074	20010629
ZA 2003000749	A	20050628	ZA 2003-749	20030128
US 2005026876	A1	20050203	US 2004-786881	20040224
US 2004214801	A1	20041028	US 2004-839023	20040504
PRIORITY APPLN. INFO.:			US 2000-216659P	P 20000707
			US 2001-275621P	P 20010313
			US 2001-895857	A2 20010629
			WO 2001-US20721	W 20010629
			US 2002-362654P	P 20020308
			US 2002-35495B	P 20020712


L4 ANSWER 12 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
US 2003-384855 B2 20030310

(Continued)

OTHER SOURCE(S): MARPAT 136:102231  
IT 365277-07-2P 365277-36-7P 365277-38-9P  
365277-57-2P 365277-58-3P 365277-59-4P  
365277-60-7P 365277-61-8P 365277-62-9P  
365277-63-0P 365277-64-1P 365277-65-2P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(preparation of 9-substituted minocycline derivs. for pharmaceutical


use as  
 antibacterial agents)  
 RN 365277-07-2 HCAPLUS  
 CN Carbamic acid,  
 [(5a,6a,7a,10a)-7,10-(aminocarbonyl)-4,7-bis(dimethylamino)-  
 5,6,6a,7,8,9,10,12-octahydro-1,8-dioxy-10,11-dihydroxy-10,12-dioxo-2-  
 methyl-3,4-dihydro-2,7-dimethylbiphenyl-6-yl ester (9CI) (RA IMPEX NDMR).

### Absolute stereochemistry




RN 365277-36-7 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,7a,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) [CA INDEX NAME]

### Absolute stereochemistry.




RN 365277-38-9 HCPLUS  
 CN Carbamic acid, 1-(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5a,6a,6,7,10,10a,12-octahydro-1,8a,11-tetrahydroxy-10,12-dioxo-2-naphthalenyl-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)  
Absolute stereochemistry.




RN 365277-57-2 HCAPLUS  
 CN Carbamothioic acid, 1,5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthalenyl)-, S-phenyl ester (9CI) (CA INDEX NAME)  
 Absolute stereochemistry

### ASSOLUTE STEREOCHEMISTRY




RN 365277-58-3 HCAPLUS  
CN Carbamic acid,  
(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-  
5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-  
naphthalenyl)-, 4-bromophenyl ester (9CI) (CA INDEX NAME)

### Absolute stereochemistry



### naphtalocenyl, 1, 4




RN 365277-60-7 HCAPLUS

CN Carbamic acid,

[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-61-8 HCAPLUS

CN Carbamic acid,

[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-62-9 HCAPLUS

CN Carbamothioic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-

bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-

Absolute stereochemistry.




RN 365277-63-0 HCAPLUS

CN Carbamic acid,

[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 3-butene ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-64-1 HCAPLUS

CN Carbamic acid,

[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-65-2 HCAPLUS

CN Carbamic acid,

[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-

5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ACCESSION NUMBER: 2001:747739 HCAPLUS

DOCUMENT NUMBER: 135:288637

TITLE: Preparation of 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heterocaryl-amino substituted tetracycline derivatives for pharmaceutical use as antibiotics

INVENTOR(S): Nelson, Mark L.; Levy, Stuart B.; Prechette, Roger; Bowser, Todd E.; Ismail, Mohamed Y.

PATENT ASSIGNEE(S): Trustees of Tufts College, USA

SOURCE: PCT Int. Appl., 88 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 10

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001074761	A1	20011011	WO 2001-US10342	20010330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TU, TM, TR, TT, TZ, UA, UG, VN, YU, ZA				
ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2404628	RA	20011011	CA 2001-2404628	20010330
AU 2001051157	A5	20011015	AU 2001-51157	20010330
US 2002103171	A1	20020801	US 2001-823884	20010330
US 6818634	B2	20041116		
EP 1272459	A1	20030108	EP 2001-924508	20010330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001009725	A	20030204	BR 2001-9725	20010330
JP 2004505012	T2	20040219	JP 2001-572456	20010330
US 2002128237	A1	20020912	US 2001-882273	20010615
US 2002147182	A1	20021010	US 2001-895796	20010629
US 6500812	B2	20021231		
ZA 2002008735	A	20031029	ZA 2002-8735	20021029
US 2004176334	A1	20040909	US 2004-186710	20040424
US 2004224927	A1	20041111	US 2004-820456	20040407
PRIORITY APPLN. INFO.:			US 2000-193879P	P 20000331
			US 2000-193972P	P 20000331
			US 2001-280367P	P 20010329
			US 1999-154701P	P 19990914
			US 2000-204158P	P 20000515
			US 2000-212030P	P 20000616
			US 2000-212139P	P 20000616
			US 2000-212471P	P 20000616


L4 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 WO 2000-US16672 W 20000616  
 US 2000-216580P P 20000707  
 US 2001-823884 A1 20010330  
 WO 2001-US10342 W 20010330  
 US 2001-882273 B1 20010615

OTHER SOURCE(S): MARPAT 135:288637  
 IT 365277-03-0P 365277-04-9P 365277-05-0P  
 365277-06-1P 365277-07-2P 365277-22-1P  
 365277-23-2P 365277-24-3P 365277-34-5P  
 365277-35-6P 365277-36-7P 365277-38-9P  
 365277-57-2P 365277-58-3P 365277-59-4P  
 365277-60-7P 365277-61-8P 365277-62-9P  
 365277-63-0P 365277-64-1P 365277-65-2P  
 365277-68-5P 365277-71-0P 365277-80-1P  
 365277-84-5P 365277-85-6P 365277-86-7P  
 365277-87-8P 365280-21-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 7- and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline derivs. for pharmaceutical use as antibiotics)


RN 365277-03-8 HCAPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-04-9 HCAPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-

L4 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 365277-07-2 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-22-1 HCAPLUS  
 CN Cholest-5-en-3-ol (3β)-, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl] carbamate (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



12/27/2005

L4 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-05-0 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-06-1 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 PAGE 1-B



RN 365277-23-2 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-24-3 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 4-methylphenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-34-5 HCAPLUS

CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-p-..... Page 26


L4 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-35-6 HCAPLUS  
 CN Carbamic acid, [(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, 2-bromoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-36-7 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 365277-59-4 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-60-7 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-61-8 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

12/27/2005

L4 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 365277-38-9 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-57-2 HCAPLUS  
 CN Carbamothioic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 8-phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-58-3 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-bromophenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 13 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 365277-62-9 HCAPLUS  
 CN Carbamothioic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 5-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-63-0 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 3-but enyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-64-1 HCAPLUS  
 CN Carbamic acid, [(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 13 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN

(Continued)




RN 365277-65-2 HCPLUS

CN Carbamic acid,

[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-68-5 HCPLUS

CN Carbamic acid,

[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 365277-71-0 HCPLUS

L4 ANSWER 13 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN

(Continued)




RN 365277-85-6 HCPLUS

CN Carbamothioic acid,

[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, O-(4-methoxyphenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-86-7 HCPLUS

CN Carbamothioic acid,

[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, O-(2,2-dimethylpropyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-87-8 HCPLUS

CN Carbamic acid,

[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, pentyl ester (9CI) (CA INDEX NAME)


12/27/2005

L4 ANSWER 13 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN Carbamic acid,

[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 4-fluorophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 365277-80-1 HCPLUS

CN Carbamothioic acid,

[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, O-(9H-fluoren-9-ylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 365277-84-5 HCPLUS


CN Carbamothioic acid,

[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, O-(4-fluorophenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 13 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.




RN 365280-21-3 HCPLUS

CN Carbamic acid,

[(5aR,6aS,7S,10aS)-9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 1-methylethylene ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

5


THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 14 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1997:327 HCAPLUS  
 DOCUMENT NUMBER: 126:31223  
 TITLE: Preparation of novel tetracycline derivatives  
 INVENTOR(S): Vu, Chi Bao  
 PATENT ASSIGNEE(S): Pfizer, Inc., USA; Vu, Chi Bao  
 SOURCE: PCT Int. Appl., 96 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9634852	A1	19961107	WO 1996-IB335	19960417
M: AU, CA, JP, MX, NZ, US				
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,				
SE CA 2219277	AA	19961107	CA 1996-2219277	19960417
AU 9651186	A1	19961121	AU 1996-51186	19960417
AU 693013	B2	19980618		
EP 823893	A1	19980218	EP 1996-907639	19960417
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI JP 11504916	T2	19990511	JP 1996-533149	19960417
US 6165599	A	20001226	US 1998-945775	19980223
PRIORITY APPLN. INFO.:			US 1995-433102	A 19950503
			WO 1996-IB335	W 19960417


OTHER SOURCE(S): MARPAT 126:31223  
 IT 184593-66-SP 184593-69-9  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 Preparation of antibacterial tetracycline deriva.  
 RN 184593-66-6 HCAPLUS  
 CN Carbamic acid,  
 [9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-  
 octahydro-1,5,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-,  
 methyl ester, [5S-(5a,5aP,6aP,7P,10aP)]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 15 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1995:55081 HCAPLUS  
 DOCUMENT NUMBER: 122:188050  
 TITLE: "Glycylcyclines". 3. 9-Aminodoxycyclinecarboxamides  
 AUTHOR(S): Barden, Timothy C.; Buckwalter, Brian L.; Testa, Raymond T.; Petersen, Peter J.; Lee, Ving J.  
 CORPORATE SOURCE: Agricultural Research Division, American Cyanamid Company, Princeton, NJ, 08543-0400, USA  
 SOURCE: Journal of Medicinal Chemistry (1994), 37(20), 3205-11  
 DOCUMENT TYPE: CODEN: JMCMAR; ISSN: 0022-2623  
 LANGUAGE: English  
 IT 161452-40-0P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 Preparation and bactericidal activity of acylaminodoxycyclines  
 RN 161452-40-0 HCAPLUS  
 CN Carbamic acid,  
 [9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-  
 octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-,  
 methyl ester, [5R-(5a,5aP,6aP,7a,10aP,alph  
 a.)-] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 14 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 184593-69-9 HCAPLUS  
 CN Carbamic acid,  
 [9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-  
 octahydro-1,5,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-,  
 phenyl ester, [5S-(5a,5aP,6aP,7P,10aP)]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 16 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1994:579403 HCAPLUS  
 DOCUMENT NUMBER: 121:179403  
 TITLE: Preparation of 7-(substituted)-8-(substituted)-9-  
 (substituted amino)-6-demethyl-6-deoxytetracyclines

as  
 INVENTOR(S): Sum, Phaik Eng; Lee, Ving J.; Hlavka, Joseph J.;  
 Testa, Raymond T.  
 PATENT ASSIGNEE(S): American Cyanamid Co., USA  
 SOURCE: Eur. Pat. Appl., 181 pp.  
 DOCUMENT TYPE: CODEN: EPXXDW


LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 582810	A1	19940216	EP 1993-109850	19930621
EP 582810	B1	20020403		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 215530	E	20020415	AT 1993-109850	19930621
PT 582810	T	20020830	PT 1993-109850	19930621
ES 2173876	T3	20021101	ES 1993-109850	19930621
CZ 289195	B6	20011114	CZ 1993-1575	19930804
SK 210171	B6	20010806	SK 1993-857	19930809
CA 2103861	AA	19940214	CA 1993-2103861	19930811
CA 2103861	C	20040727		
JP 06228072	A2	19940816	JP 1993-217927	19930811
JP 3639313	B2	20050420		
NO 9302872	A	19940214	NO 1993-2872	19930812
AU 9344501	A1	19940217	AU 1993-44601	19930812
AU 674524	B2	19970102		
ZA 9305892	A	19940310	ZA 1993-5892	19930812
HU 64945	A2	19940328	HU 1993-2333	19930812
HU 213269	B	19970428		
IL 106677	A1	19980615	IL 1993-106677	19930812
PL 174022	B1	19980630	PL 1993-300066	19930812
PL 174127	B1	19980630	PL 1993-318908	19930812
PL 174230	B1	19980721	PL 1993-316767	19930812
IL 119750	A1	19980924	IL 1993-119750	19930812
IL 119751	A1	19980924	IL 1993-119751	19930812
PL 175487	B1	19980129	PL 1993-316768	19930812
RU 2127255	C1	19990310	RU 1993-48636	19930812
CN 1090267	A	19940803	CN 1993-109819	19930813
CN 1048719	B	20000126		
US 5430162	A	19950704	US 1994-214992	19940321
US 5495018	A	19960227	US 1994-352407	19941208
US 5886175	A	19990323	US 1994-352310	19941208
US 5512553	A	19960430	US 1995-454966	19950531
PRIORITY APPLN. INFO.:			US 1992-920598	A 19920813
			IL 1993-106677	A3 19930812
			US 1994-214992	B3 19940321

OTHER SOURCE(S): MARPAT 121:179403  
 IT 157579-07-29 157579-18-5P 157579-22-1P  
 157579-23-2P 157579-28-7P 157579-29-8P


L4 ANSWER 16 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 157579-30-18 157579-31-2P 157579-36-7P  
 157579-37-8P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); (prepn. of, as antibiotic)  
 RN 157579-07-2 HCPLUS  
 CN Carbamic acid, [9-(aminocarbonyl)-3-chloro-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, methyl ester, [5aR-(5aa,6aa,7a,10a.alpha.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157579-18-5 HCPLUS  
 CN Carbamic acid, [9-(aminocarbonyl)-7-(dimethylamino)-3-fluoro-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, methyl ester, [5aR-(5aa,6aa,7a,10a.alpha.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 157579-22-1 HCPLUS  
 CN Carbamic acid, [9-(aminocarbonyl)-3-chloro-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, 2-(dimethylamino)ethyl ester, monohydrochloride, [5aR-(5aa,6aa,7a,10aa)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 16 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 157579-23-2 HCPLUS  
 CN 2-Naphthaceneacboxamide, 8-chloro-9-[([(dimethylamino)oxy]carbonyl]amino)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, [4S-(4a,4aa,5aa,12aa)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 157579-28-7 HCPLUS  
 CN Carbamic acid, [9-(aminocarbonyl)-7-(dimethylamino)-3-fluoro-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, methyl ester, monohydrochloride, [5aR-(5aa,6aa,7a,10aa)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 16 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl


RN 157579-29-8 HCPLUS  
 CN Methanesulfonic acid, trifluoro-, 8-(aminocarbonyl)-10-(dimethylamino)-5,6a,7,10,10a,11,11a,12-octahydro-4,6,6a,9-tetrahydroxy-3-[(methoxycarbonyl)amino]-5,7-dioxo-2-naphthacenyl ester, [6aS-(6aa,10a,10aa)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157579-30-1 HCPLUS  
 CN 2-Naphthaceneacboxamide, 8-chloro-4-(dimethylamino)-9-[(dimethylamino)oxy]carbonyl]amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12a-tetrahydroxy-1,11-dioxo-, [4S-(4a,4aa,5aa,12aa)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 157579-31-2 HCPLUS  
 CN 2-Naphthaceneacboxamide, 8-chloro-9-[(dimethylamino)oxy]carbonyl]amino)-

12/27/2005 4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-


L4 ANSWER 16 OF 17 HCPLUS COPYRIGHT 2005 ACS on STN (Continued)  
 1,11-dioxo-, [4S-(4a,4ac,5aa,12aa)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 157579-36-7 HCPLUS  
 CN Carbamic acid, [9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-3-iodo-10,12-dioxo-2-naphthacenyl]-, methyl ester, [5aR-(5aa,6aa,7a,10aa)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 157579-37-8 HCPLUS  
 CN Carbamic acid, [9-(aminocarbonyl)-3-bromo-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-, methyl ester, [5aR-(5aa,6aa,7a,10aa)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L4 ANSWER 17 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1992-603237 HCAPLUS  
 DOCUMENT NUMBER: 119-203237  
 TITLE: Preparation of 7-substituted-9-substituted  
 amino-6-demethyl-6-deoxytetraacyclines  
 INVENTOR(S): Hlavka, Joseph J.; Sum, Phaik Eng; Gluzman, Yakov;  
 Lee, Ving J.; Ross, Adma A.  
 PATENT ASSIGNEE(S): American Cyanamid Co., USA  
 SOURCE: Eur. Pat. Appl., 209 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 536515	A1	19920414	EP 1992-114281	19920821
EP 536515	B1	20011219		
AT 211128	R, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE	20020115	AT 1992-114281	19920821
PT 536515	T	20020531	PT 1992-114281	19920821
ES 2169254	T3	20020616	ES 1992-114281	19920821
HU 63145	A2	19930728	HU 1992-3110	19920930
HU 219973	B	20011028		
CZ 284159	B6	19980812	CZ 1992-2984	19920930
CZ 284209	B6	19980916	CZ 1997-3093	19920930
SK 280837	B6	20000814	SK 1992-2984	19920930
IL 103320	A1	19981206	IL 1992-103320	19921001
IL 119590	A1	19990312	IL 1992-119590	19921001
CA 2079692	AA	19930405	CA 1992-2079692	19921002
CA 2079692	C	20040608		
NO 9203857	A	19930405	NO 1992-3857	19921002
NO 301472	B1	19971103		
AU 9226183	A1	19930408	AU 1992-26183	19921002
AU 654049	B2	19941020		
ZA 9207607	A	19930413	ZA 1992-7607	19921002
PL 172282	B1	19970829	PL 1992-310717	19921002
PL 173311	B1	19980227	PL 1992-296143	19921002
PL 175597	B1	19990331	PL 1992-310718	19921002
PL 176333	B1	19990531	PL 1992-310719	19921002
FI 114911	B1	20005131	FI 1992-4454	19921002
CH 1072172	A	19930519	CN 1992-112130	19921003
CH 1046240	B	20000112		
JP 05255219	A2	19931005	JP 1992-288114	19921005
JP 3166863	B2	20010711		
US 5494903	A	19960227	US 1994-286096	19940804
US 5529990	A	19960625	US 1995-455446	19950531
US 553117	A	19960625	US 1995-455923	19950531
HK 1011348	A1	20020412	HK 1998-112374	19981127
PRIORITY APPLN. INFO.:			US 1991-771576	A 19911004
			US 1992-926091	B1 19920813
			IL 1992-103320	A3 19921001



L4 ANSWER 17 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued)





Absolute stereochemistry.



Absolute stereochemistry.



Absolute stereochemistry.




12/27/2005

L4 ANSWER 17 OF 17 HCAPLUS COPYRIGHT 2005 ACS on STN (Continued) US 1994-286096 A3 19940804

OTHER SOURCE(S): MARPAT 119-203237  
**IT 150231-22-4P 150231-23-5P 150251-75-5P**  
**150251-76-6P 150251-77-7P 150251-78-8P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation of, as antibacterial)  
**RN 150231-22-4 HCAPLUS**  
**CN Carbamic acid, (9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl)-, 2-(diethylamino)ethyl ester, monohydrochloride, [5R-(5a,5a,6a,6a,7a,10a)]- (9CI) (CA INDEX NAME)**


Absolute stereochemistry.




● HCl

**RN 150231-23-5 HCAPLUS**  
**CN Carbamic acid, (9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl)-, 2-propenyl ester, monohydrochloride, [5R-(5a,5a,6a,6a,7a,10a)]- (9CI) (CA INDEX NAME)**

Absolute stereochemistry.




Absolute stereochemistry.



**RN 150251-78-8 HCAPLUS**  
**CN Carbamic acid, (9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl)-, 2-propenyl ester, [5R-(5a,5a,6a,6a,7a,10a)]- (9CI) (CA INDEX NAME)**

Absolute stereochemistry.




**RN 150251-79-5 HCAPLUS**  
**CN Carbamic acid, (9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl)-, methyl ester, [5R-(5a,5a,6a,6a,7a,10a)]- (9CI) (CA INDEX NAME)**

CM 1

CRN 150251-75-5  
 CMF C26 H32 N4 O9

Absolute stereochemistry.



Page 31

CM 2

CRN 7664-93-9  
CMF H2 O4 S




RN 150521-70-3 HCAPLUS  
CN Carbamic acid, [9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]-, ethenyl ester, [5R-(5a,5am,6ac,7a,10so)]-, sulfate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 150251-77-7  
CMF C27 H32 N4 O9

Absolute stereochemistry.



CM 2

CRN 7664-93-9  
CMF H2 O4 S



Andrew Freistein 10/786,710

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	62.53	224.07

STN INTERNATIONAL LOGOFF AT 10:00:08 ON 23 DEC 2005